Company intelligence / Profile preview

Trevi Therapeutics

New Haven, Connecticut, United Statestrevitherapeutics.com ↗

Ownership: Public · TRVI
Development stage: Phase 2

Overview

Positive Phase 2a RIVER trial results for RCC announced in March 2025 showed 67% reduction in 24-hour cough frequency from baseline (p<0.0001) and 57% placebo-adjusted change. Previous Phase 2 CANAL trial showed 75% reduction in daytime cough frequency in IPF patients. Currently conducting Phase 2b CORAL trial in IPF patients with chronic cough with topline results expected in Q2 2025.

Therapeutic areas: Pulmonology
Modalities: Small molecules (oral nalbuphine ER)
Industry: Biotech

Drug pipeline

1 asset

haduvio

Financials

Market cap: $2.4B
Total revenue: $0
Enterprise value: $2.1B

Beyond the preview

Go deeper on Trevi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trevi Therapeutics.

Explore the full profile